Ore Pharmaceuticals is a commercial drug development company. We apply our proprietary know how in integrative pharmacology to identify potential new uses for drug candidates. Our goal is to meet the demands of the pharmaceutical industry by supplying development stage drug compounds to enrich drug development pipelines. We do this in two ways: we identify uses for stalled or failed drug compounds provided by our pharmaceutical partners, and, for our own pipeline, we identify new uses for drug compounds available in the public domain. Our own pipeline may also include compounds that our pharmaceutical partners decide not to develop for new uses we identify. We currently have one compound, GL1001, in our own development pipeline for which we have identified potential new therapeutic uses to treat inflammatory bowel disease (IBD, including ulcerative colitis and Crohn’s disease) and other conditions. GL1001 has shown indications of efficacy at relevant doses in in vivo testing for IBD. We intend to initiate clinical testing of GL1001 in 2008 while actively seeking to out-license or partner the further clinical development and commercialization of the compound. Visit us at orepharma.com or call 1-877-ORE-PHRM.

Ore Pharmaceuticals welcomes discussions with pharmaceutical companies looking to identify possible new indications for their drug compounds. As your partner, we work to find new development paths for your failed, stalled, or deprioritized clinical-stage candidates. Our unique, integrative pharmacology approach allows us to assess hundreds of human disease indications for each analyzed compound.

In addition, Ore Pharmaceuticals seeks to out-license or co-develop drug candidates in our proprietary drug development pipeline and we welcome discussions with interested pharmaceutical and biotechnology companies.